Characterisation of demographic and clinical variables in patients with SpA with HLA-B27 and HLA-B15
| Variable | HLA-B15 (n=34) | HLA-B27 (n=70) | P value |
|---|---|---|---|
| Age (years) median±SD | 35.7±10.0 | 35.8±13.6 | 0.97 |
| Age of onset (years) median±SD | 28.2±9.4 | 27.7±10.5 | 0.81 |
| Duration disease (years) median (IQR) | 3.4 (2–12) | 3.6 (1–12) | 0.86 |
| Gender—M/F (%) | 15/19 (44/56) | 55/15 (79/21) | <0.001 |
| Ratio—M:F | 0.8:1 | 3.7:1 | |
| ESSG criteria | |||
| AS (n=54) | 13 | 41 | 0.08 |
| uSpA (n=32) | 17 | 15 | 0.006 |
| ReA (n=18) | 4 | 14 | 0.44 |
| ASAS criteria | |||
| axSpA | |||
| Patients with axSpA (n=97) | 27 | 70 | <0.001 |
| Patients with pure axSpA (n=10) | 0 | 10 | 0.05 |
| Patients with mixed ax/pSpA (n=87) | 27 | 60 | 0.6 |
| pSpA | |||
| Patients with pSpA (n=94) | 34 | 60 | |
| Patients with pure pSpA (n=4) | 4 | 0 | 0.029 |
| Patients with mixed ax/pSpA (n=90) | 30 | 60 |
AS, ankylosing spondylitis; ASAS, Assessment of Spondyloarthritis International Society; axSpA, axial SpA; ESSG, European Spondyloarthropathy Study Group; HLA, human leukocyte antigen; pSpA, peripheral SpA; ReA, reactive spondyloarthritis; SpA, spondyloarthritis; uSpA, undifferentiated spondyloarthritis.